This report is the second study conducted by Charles River Associates on the role and impact of Health Technology Assessment (HTA) worldwide. The report assesses the performance of the HTA process in 16 countries with mature or developing HTA systems according to international best practice principles.
To read the report, please click below.
Rare disease PMA trends in France: Price achieved vs. disease prevalence
In this installment, we examine the relationship between launch prices in France and disease prevalence as reported in the Haute Autorité de Santé assessments.